PLEOPHARMA, INC.
PHOENIXVILLE, PA · Founded 2020 · CIK 0001801323 · Biotech · Private
Small molecule therapeutics targeting immune-oncology pathways
pleopharma.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $17M
- 3 Form D · Aug 2025
- 14 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 2 granted · 1 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $130,000 | |
| Private capital raised | Form D · SEC | $11,122,252 | |
| Private capital raised | Form D · SEC | $6,150,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1888 | RETROVIROX, INC. | — | — |
| 1889 | Cotinga Pharmaceuticals Inc. | — | $3.0M |
| 1890 | Antlia Bioscience, Inc. | — | $6.9M |
| 1891 | PLEOPHARMA, INC. | — | $17M |
| 1892 | D2G ONCOLOGY, INC. | — | $6.6M |
| 1893 | OCATA THERAPEUTICS, INC. | — | — |
| 1894 | CELLECTAR, Inc. | — | $2.7M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- PAUL BISARODirector
- Daniel CartwrightExecutive Officer
- DANIEL CARTWRITGHTExecutive Officer
- Jay ConstantineDirector · Executive Officer · Promoter
- Ginger ConstantineDirector · Executive Officer · Promoter
- GINGER CONSTANTINEDirector · Executive Officer
- JAY CONSTANTINEDirector
- Robert FinizioDirector · Promoter
- ROBERT FINIZIODirector
- Sarah HassanDirector
- Timothy McInerneyDirector
- Bisaro PaulDirector
- Thomas PocheExecutive Officer
- THOMAS POCHEExecutive Officer
- Brij SharmaDirector
- Thompson TommyDirector
Patents
- Methods And Compositions For Treating Cannabis Use Disorder And Mitigating Cannabinoid Withdrawalapplication
- Methods And Compositions For Treating Cannabis Use Disorder And Mitigating Cannabinoid Withdrawalgranted
- Methods And Compositions For Treating Cannabis Use Disorder And Mitigating Cannabinoid Withdrawalgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.